公开(公告)号：US20230382932A1

公开(公告)日：2023-11-30

申请号：US18225589

申请日：2023-07-24

申请人： PFIZER INC.

发明人： Martin James WYTHES ,  Indrawan James MCALPINE ,  Ryan PATMAN ,  Eugene Yuanjin RUI ,  Andrew FENSOME ,  Andreas MADERNA ,  Mehran JALAIE ,  Ketan S. GAJIWALA

IPC分类号： C07F9/6574 ,  A61K47/68 ,  A61P35/00 ,  C07H19/213

CPC分类号： C07F9/65744 ,  A61K47/6801 ,  A61P35/00 ,  C07H19/213

摘要： Compounds of the general formula (I):




or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

公开(公告)号：US20230382892A1

公开(公告)日：2023-11-30

申请号：US18322844

申请日：2023-05-24

申请人： Pfizer Inc.

发明人： Ariamala Gopalsamy ,  Shawn Cabral ,  Agustin Casimiro Garcia ,  Ming Zhu Chen ,  Chulho Choi ,  Robert Lee Dow ,  Olugbeminiyi Omezia Fadeyi ,  David Hepworth ,  Jayasankar Jasti ,  Lyn Howard Jones ,  Arjun Venkat Narayanan ,  Mihir Dineshkumar Parikh ,  David Walter Piotrowski ,  Lee Richard Roberts ,  Ralph Pelton Robinson, Jr. ,  Hatice Gizem Yayla

IPC分类号： C07D401/14 ,  A61P7/06 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61P7/06 ,  C07D471/04 ,  A61K45/06

摘要： The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
More particularly the invention relates to HbS modulators of formula (I)






or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description.




HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

公开(公告)号：US11820748B2

公开(公告)日：2023-11-21

申请号：US18160442

申请日：2023-01-27

申请人： Pfizer Inc.

发明人： Elaine Greer ,  Stephen Anderson ,  Mark Maloney ,  Shu Yu ,  Ekaterina Albert ,  Emily Rigsbee

IPC分类号： C07D233/88 ,  A61K31/40

CPC分类号： C07D233/88 ,  A61K31/40 ,  C07B2200/13

摘要： The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

公开(公告)号：US11814435B2

公开(公告)日：2023-11-14

申请号：US17005073

申请日：2020-08-27

申请人： PFIZER INC.

发明人： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC分类号： C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K31/454 ,  A61K31/704 ,  A61K31/69 ,  A61K47/68 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K31/454 ,  A61K31/69 ,  A61K31/704 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6801 ,  A61K47/6849 ,  C07K16/2803 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00

摘要： The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US11802121B2

公开(公告)日：2023-10-31

申请号：US18049052

申请日：2022-10-24

申请人： Pfizer Inc.

发明人： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC分类号： A61K31/496 ,  A61K31/4545 ,  C07D401/14 ,  C07D487/04 ,  A61P3/00 ,  A61P15/10 ,  A61P17/06 ,  A61P9/10 ,  A61P19/06 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  A61P1/16 ,  A61P25/02 ,  A61P3/04 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/16 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61K31/4545 ,  A61K31/496 ,  A61P1/00 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

摘要： Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20230340151A1

公开(公告)日：2023-10-26

申请号：US17975508

申请日：2022-10-27

申请人： PFIZER INC.

发明人： Chew Shun CHANG ,  Gurkan GUNTAS ,  Madan KATRAGADDA ,  Divya MATHUR ,  Adam Reid ROOT ,  Lidia MOSYAK ,  Edward Roland LAVALLIE

IPC分类号： C07K16/40 ,  A61P35/00

CPC分类号： C07K16/40 ,  A61P35/00 ,  A61K45/06

摘要： The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.

公开(公告)号：US20230340137A1

公开(公告)日：2023-10-26

申请号：US18025879

申请日：2021-09-10

申请人： PFIZER INC.

发明人： Nathalie Annie BARDY BOUXIN ,  Eloisa Virginia BARRY ,  John Andrew BLAKE-HASKINS ,  Geoffrey Wing-Lynn CHAN ,  Jeffrey CHOU ,  Mohamed A ELMELIEGY ,  Heike Iris KRUPKA ,  Kai Hsin LIAO ,  Erik Rene VANDENDRIES ,  Andrea VIQUEIRA ,  Paul Stephen WISSEL ,  Anne YVER

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/138 ,  A61K31/167 ,  A61K39/00

CPC分类号： C07K16/2878 ,  C07K16/2818 ,  A61P35/00 ,  A61K39/3955 ,  A61K31/573 ,  C07K16/2896 ,  A61K31/4439 ,  A61K31/138 ,  C07K16/2809 ,  A61K31/167 ,  C07K2317/53 ,  A61K2039/507 ,  C07K2317/31 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2317/565 ,  A61K2039/545

摘要： The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.

公开(公告)号：US20230339930A1

公开(公告)日：2023-10-26

申请号：US18004996

申请日：2021-07-07

申请人： Pfizer Inc.

发明人： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Qingyi Yang

IPC分类号： C07D417/14 ,  A61P31/14

CPC分类号： C07D417/14 ,  A61P31/14

摘要： The invention relates to compounds of Formula I




wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US20230329630A1

公开(公告)日：2023-10-19

申请号：US18043271

申请日：2021-08-30

申请人： PFIZER INC.

发明人： Shyamal Patel ,  Paul William Wacnik ,  Kara Chappie ,  Robert Mather ,  Brian Tracey ,  Maria del Mar Santamaria Serra

IPC分类号： A61B5/00 ,  A61B5/08 ,  A61B7/00 ,  A61K31/675 ,  A61K38/06 ,  G10L15/02 ,  G10L25/66 ,  G10L15/26 ,  G10L15/22 ,  G16H10/60 ,  G16H40/20 ,  G16H20/10 ,  G16H50/30

CPC分类号： A61B5/4803 ,  A61B5/08 ,  A61B5/7275 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/4842 ,  A61B7/003 ,  A61B5/7278 ,  A61K31/675 ,  A61K38/06 ,  G10L15/02 ,  G10L25/66 ,  G10L15/26 ,  G10L15/22 ,  G16H10/60 ,  G16H40/20 ,  G16H20/10 ,  G16H50/30 ,  G10L2015/025

摘要： Technology is disclosed for monitoring a user's respirator), condition and provide decision support by analyzing a user's audio data. Spoken phonemes may be detected within audio data, and acoustic features may be extracted for the phonemes. A distance metric may be computed to compare phoneme feature sets of a user. Based on the comparison, a determination about the user's respiratory condition, such as whether the user has a respiratory condition (e.g., an infection) and/or whether the condition is changing, may be made. Some aspects include predicting the user's respiratory condition in the future utilizing the phoneme feature sets. Decision support tools in the form of computer applications or services may utilize the detected or predicted respiratory condition information to initiate an action for treating a current condition or mitigating a future risk.

公开(公告)号：US11780853B2

公开(公告)日：2023-10-10

申请号：US17539948

申请日：2021-12-01

申请人： PFIZER INC.

发明人： Hui Li ,  Seiji Nukui ,  Stephanie Anne Scales ,  Min Teng ,  Chunfeng Yin

IPC分类号： A61K31/4162 ,  C07D487/04 ,  C07D519/00

CPC分类号： C07D519/00 ,  C07D487/04

摘要： The present invention relates to protein kinase C beta II inhibiting compounds of Formula (A):






wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. The invention further relates to pharmaceutical compositions comprising the compounds of Formula (A), or pharmaceutically acceptable salts thereof, and methods for treating a disease or disorder selected from the group consisting of Alzheimer's disease, cancer, a cardiovascular disease, a central nervous system disorder, depression, a dermatological disease, diabetes mellitus, a complication arising from diabetes mellitus, a disease in which the liver is a target organ inflammation, an inflammatory disorder, ischemia, and a viral disease.